This job has expired

You will need to login before you can apply for a job.

Director of Preclinical in vitro Pharmacology

Intellia Therapeutics
Cambridge, MA
Start date
Feb 1, 2023

View more

Science/R&D, Pharmacology
Required Education
Position Type
Full time
Genetown, Best Places to Work

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

Intellia is looking for a Director of PreClinical in vitro pharmacology to support the advancement of genome editing products into the clinic. Within this leadership role, you will be responsible for the implementation and execution of cell-based assays to support in vitro pharmacology and genotoxicity data packages enabling in vivo and cell therapy program progression into clinical trials. You will be responsible for the documentation enabling regulatory filings including data documentation and quality control. This is a highly visible leadership position serving on multiple therapeutic program teams supporting regulatory filings and documentation. In this role you will:

  • Manage a team of cell and molecular biologists focused on the execution of cell-based assays to support in vitro pharmacology and genotoxicity data packages in support of regulatory filings and clinical programs

  • Transition cell-based assays from research into development through optimization and validation to apply to regulatory programs implementing SOPs, standards, etc

  • Oversee data quality and writing of technical reports, briefing books, INDs, CTAs and other requests from global regulatory authorities

  • Partner with computational biology, software engineering, and PreClnical Project Management on data analysis, data capture, and documentation

  • Partner with Genomic Innovation to develop and align cell-based assays to support pipeline programs and platform technology

  • Partner with PreClincial NGS to produce in vitro samples for genotoxicity analysis

  • Serve as SME for cell-based methods in support of in vivo and cell therapy development program advancement to the clinic

  • Effectively interact with other functional area experts in a program team environment to execute on development program progression to the clinic

  • Partner with Quality to build out a GLP-like environment to handle GMP sample experimentation and documentation

  • Work with PreClinical Project Management to align resources and timelines

  • Partner with regulatory, clinical, and program team leads to support regulatory filings

  • Support the development of direct reports through coaching, mentoring, leveraging their strengths, and providing opportunities for career growth

About You:

The Director of PreClinical in vitro pharmacology will have demonstrated expertise and in cell-based assays, primary cell culture techniques, molecular biology, and gene editing approaches, experience in supporting gene editing therapies into the clinic including engaging with health authorities both written and verbally.

  • Ph.D. with 10 years of directly related industry experience.

  • Experience managing a high-performing team in a fast-paced environment.

  • Experience juggling multiple high-priority projects and balancing resources.

  • Experience in writing and documentation to support regulatory filings as well as response to health authority questions and interacting with health authorities.

Meet your future team:

You will be an SME in vitro pharmacology working closely with PreClinical NGS, Computational Biology, Toxicology, Genomics Innovation and PreClinical Project Management to support the development of genome editing-based therapeutics into the clinic. We are accountable for enabling our programs in early research to reach development candidate nomination through regulatory filing and into clinical trials.

In this key leadership role, you will report directly to the Vice President, Genomic Operations, who instills a culture of teamwork, respect, inclusion, collaboration, and communication ensuring that each team member strives to reach their professional and personal potential.

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.


Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA


Find Us
Intellia Therapeutics
(857) 285-6200
40 Erie Street

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert